Recently, the combination of atezolizumab (anti-PD-L1 antibody) and bevacizumab (anti-angiogenesis agent), the IMbrave150 study, and the combination of sintilimab (anti-PD-1 antibody) and a bevacizumab biosimilar, the ORIENT-32 trial, have successfully outperformed sorafenib as the first-line therapy in advanced HCC [9, 10]. The gene discussed is CD274; the disease is hepatocellular carcinoma.